These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

272 related items for PubMed ID: 38234208

  • 1. Two years with GIOIA 'Effects of gliflozins and gliptins on markers of cardiovascular damage in type 2 diabetes': A prospective, multicentre, quasi-experimental study on sodium-glucose cotransporter 2 and dipeptidyl peptidase-4 inhibitors in diabetes clinical practice.
    Longo M, Caruso P, Scappaticcio L, Maiorino MI, Bellastella G, Capuano A, Esposito K, Giugliano D.
    Diabetes Obes Metab; 2024 Apr; 26(4):1492-1501. PubMed ID: 38234208
    [Abstract] [Full Text] [Related]

  • 2. Metabolic effectiveness of gliflozins and gliptins in the routine clinical practice of patients with type 2 diabetes: preliminary results from GIOIA, a prospective multicentre study.
    Esposito K, Longo M, Maiorino MI, Petrizzo M, Gicchino M, Bellastella G, Giugliano D.
    Diabetes Res Clin Pract; 2019 Sep; 155():107787. PubMed ID: 31326454
    [Abstract] [Full Text] [Related]

  • 3. Association between sodium glucose co-transporter 2 inhibitors and a reduced risk of heart failure in patients with type 2 diabetes mellitus: a real-world nationwide population-based cohort study.
    Kim YG, Han SJ, Kim DJ, Lee KW, Kim HJ.
    Cardiovasc Diabetol; 2018 Jun 23; 17(1):91. PubMed ID: 29935543
    [Abstract] [Full Text] [Related]

  • 4. Sodium-glucose co-transporter-2 inhibitors and the risk of venous thromboembolism: A nationwide population-based study and meta-analysis.
    Tsai HR, Lin YJ, Yeh JI, Huang YC, Liu PP, Peng CC, Hsu JY, Lee YC, Loh CH, Lin SM, Huang HK.
    Diabetes Metab Res Rev; 2024 Feb 23; 40(2):e3739. PubMed ID: 37862117
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Characteristics of new users of recent antidiabetic drugs in Canada and the United Kingdom.
    Brunetti VC, St-Jean A, Dell'Aniello S, Fisher A, Yu OHY, Bugden SC, Daigle JM, Hu N, Alessi-Severini S, Shah BR, Ronksley PE, Lix LM, Ernst P, Filion KB, Canadian Network for Observational Drug Effect Studies (CNODES) Investigators.
    BMC Endocr Disord; 2022 Sep 29; 22(1):241. PubMed ID: 36175881
    [Abstract] [Full Text] [Related]

  • 7. Association of Sodium-Glucose Cotransporter-2 Inhibitors With Incident Atrial Fibrillation in Older Adults With Type 2 Diabetes.
    Zhuo M, D'Andrea E, Paik JM, Wexler DJ, Everett BM, Glynn RJ, Kim SC, Patorno E.
    JAMA Netw Open; 2022 Oct 03; 5(10):e2235995. PubMed ID: 36219443
    [Abstract] [Full Text] [Related]

  • 8. Should Baseline Hemoglobin A1c or Dose of SGLT-2i Guide Treatment With SGLT-2i Versus DPP-4i in People With Type 2 Diabetes? A Meta-Analysis and Systematic Review.
    Uhrig JL, Page SO, Mishriky BM, Patil SP, Powell JR, Sewell K, Mian MR, Cummings DM.
    J Clin Pharmacol; 2020 Aug 03; 60(8):980-991. PubMed ID: 32396236
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The association of amputations and peripheral artery disease in patients with type 2 diabetes mellitus receiving sodium-glucose cotransporter type-2 inhibitors: real-world study.
    Paul SK, Bhatt DL, Montvida O.
    Eur Heart J; 2021 May 07; 42(18):1728-1738. PubMed ID: 33289789
    [Abstract] [Full Text] [Related]

  • 12. Association of Sodium-Glucose Cotransporter-2 Inhibitors With Fracture Risk in Older Adults With Type 2 Diabetes.
    Zhuo M, Hawley CE, Paik JM, Bessette LG, Wexler DJ, Kim DH, Tong AY, Kim SC, Patorno E.
    JAMA Netw Open; 2021 Oct 01; 4(10):e2130762. PubMed ID: 34705014
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Lower heart failure and chronic kidney disease risks associated with sodium-glucose cotransporter-2 inhibitor use in Japanese type 2 diabetes patients without established cardiovascular and renal diseases.
    Komuro I, Kadowaki T, Bodegård J, Thuresson M, Okami S, Yajima T.
    Diabetes Obes Metab; 2021 Apr 01; 23 Suppl 2():19-27. PubMed ID: 33835641
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Outcomes of SGLT-2i and GLP-1RA Therapy Among Patients With Type 2 Diabetes and Varying NAFLD Status.
    Bea S, Jeong HE, Filion KB, Yu OH, Cho YM, Lee BH, Chang Y, Byrne CD, Shin JY.
    JAMA Netw Open; 2023 Dec 01; 6(12):e2349856. PubMed ID: 38153732
    [Abstract] [Full Text] [Related]

  • 18. Glycaemic control efficacy of switching from dipeptidyl peptidase-4 inhibitors to oral semaglutide in subjects with type 2 diabetes: A multicentre, prospective, randomized, open-label, parallel-group comparison study (SWITCH-SEMA 2 study).
    Furusawa S, Nomoto H, Yokoyama H, Suzuki Y, Tsuzuki A, Takahashi K, Miya A, Kameda H, Cho KY, Takeuchi J, Nagai S, Taneda S, Kurihara Y, Nakamura A, Atsumi T, SWITCH-SEMA 2 study group.
    Diabetes Obes Metab; 2024 Mar 01; 26(3):961-970. PubMed ID: 38073422
    [Abstract] [Full Text] [Related]

  • 19. Clinical inertia among patients with type 2 diabetes mellitus treated with DPP-4i and/or SGLT-2i.
    Lanzinger S, Schmid SM, Welp R, Zimmermann A, Fasching P, Wagner S, Holl RW.
    Diabetes Res Clin Pract; 2018 Dec 01; 146():162-171. PubMed ID: 30367902
    [Abstract] [Full Text] [Related]

  • 20. Influence of early use of sodium-glucose transport protein 2 inhibitors, glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors on the legacy effect of hyperglycemia.
    Deng S, Zhao H, Chai S, Sun Y, Shen P, Lin H, Zhan S.
    Front Endocrinol (Lausanne); 2024 Dec 01; 15():1369908. PubMed ID: 38803473
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.